Pathologic studies of acute rejection of mismatched feline musculocutaneous flaps: Effect of cyclosporine and prednisolone

Clare R. Gregory, Ira M. Gourley, Helena Ferreira, Peter F Moore, Karen A. Imondi, John D. Patz, Teri A. Gregory, Niels C Pedersen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The gracilis musculocutaneous flap was developed as an allograft model to study acute rejection and immunosuppression in the cat. Twelve adult cats received a MLC incompatible flap. Six of the cats received cyclosporine oral solution and prednisolone (0.5 mg/kg/24 hr) for 100 days and six cats were not treated. Trough whole-blood levels of cyclosporine in the treatment group were maintained at approximately 750 ng/ml for 70 days, then 500 ng/ml for the remaining 30 days. Three flaps failed due to technical problems; 5 flaps were studied in the treatment group and 4 in the untreated group. All 5 flaps in the treatment group survived the 100 day treatment period and were rejected 30±26 days following cessation of treatment. Prior to discontinuation of treatment, with the exception of one cat, inflammatory changes associated with rejection were not observed in biopsy specimen. The flaps in the untreated group survived 13±1.5 days. Histopathologic examination of the flaps revealed little difference in the appearance of acute rejection and rejection after cessation of therapy. The most prominent lesion was a vasculitis with extensive perivascular lymphohistocytic inflammation. The lymphoid infiltrates consisted predominantly of T cells of both major classes (CD4 and CD8). Full-thickness epidermal necrosis and subsequent bacterial invasion followed vascular compromise.

Original languageEnglish (US)
Pages (from-to)1170-1175
Number of pages6
JournalTransplantation
Volume51
Issue number6
StatePublished - 1991

Fingerprint

Myocutaneous Flap
Felidae
Prednisolone
Cyclosporine
Cats
Therapeutics
Withholding Treatment
Vasculitis
Immunosuppression
Allografts
Blood Vessels
Necrosis
Inflammation
T-Lymphocytes
Biopsy

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Pathologic studies of acute rejection of mismatched feline musculocutaneous flaps : Effect of cyclosporine and prednisolone. / Gregory, Clare R.; Gourley, Ira M.; Ferreira, Helena; Moore, Peter F; Imondi, Karen A.; Patz, John D.; Gregory, Teri A.; Pedersen, Niels C.

In: Transplantation, Vol. 51, No. 6, 1991, p. 1170-1175.

Research output: Contribution to journalArticle

Gregory, CR, Gourley, IM, Ferreira, H, Moore, PF, Imondi, KA, Patz, JD, Gregory, TA & Pedersen, NC 1991, 'Pathologic studies of acute rejection of mismatched feline musculocutaneous flaps: Effect of cyclosporine and prednisolone', Transplantation, vol. 51, no. 6, pp. 1170-1175.
Gregory, Clare R. ; Gourley, Ira M. ; Ferreira, Helena ; Moore, Peter F ; Imondi, Karen A. ; Patz, John D. ; Gregory, Teri A. ; Pedersen, Niels C. / Pathologic studies of acute rejection of mismatched feline musculocutaneous flaps : Effect of cyclosporine and prednisolone. In: Transplantation. 1991 ; Vol. 51, No. 6. pp. 1170-1175.
@article{9eb75a1288ad46ee99223f85620c4faf,
title = "Pathologic studies of acute rejection of mismatched feline musculocutaneous flaps: Effect of cyclosporine and prednisolone",
abstract = "The gracilis musculocutaneous flap was developed as an allograft model to study acute rejection and immunosuppression in the cat. Twelve adult cats received a MLC incompatible flap. Six of the cats received cyclosporine oral solution and prednisolone (0.5 mg/kg/24 hr) for 100 days and six cats were not treated. Trough whole-blood levels of cyclosporine in the treatment group were maintained at approximately 750 ng/ml for 70 days, then 500 ng/ml for the remaining 30 days. Three flaps failed due to technical problems; 5 flaps were studied in the treatment group and 4 in the untreated group. All 5 flaps in the treatment group survived the 100 day treatment period and were rejected 30±26 days following cessation of treatment. Prior to discontinuation of treatment, with the exception of one cat, inflammatory changes associated with rejection were not observed in biopsy specimen. The flaps in the untreated group survived 13±1.5 days. Histopathologic examination of the flaps revealed little difference in the appearance of acute rejection and rejection after cessation of therapy. The most prominent lesion was a vasculitis with extensive perivascular lymphohistocytic inflammation. The lymphoid infiltrates consisted predominantly of T cells of both major classes (CD4 and CD8). Full-thickness epidermal necrosis and subsequent bacterial invasion followed vascular compromise.",
author = "Gregory, {Clare R.} and Gourley, {Ira M.} and Helena Ferreira and Moore, {Peter F} and Imondi, {Karen A.} and Patz, {John D.} and Gregory, {Teri A.} and Pedersen, {Niels C}",
year = "1991",
language = "English (US)",
volume = "51",
pages = "1170--1175",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pathologic studies of acute rejection of mismatched feline musculocutaneous flaps

T2 - Effect of cyclosporine and prednisolone

AU - Gregory, Clare R.

AU - Gourley, Ira M.

AU - Ferreira, Helena

AU - Moore, Peter F

AU - Imondi, Karen A.

AU - Patz, John D.

AU - Gregory, Teri A.

AU - Pedersen, Niels C

PY - 1991

Y1 - 1991

N2 - The gracilis musculocutaneous flap was developed as an allograft model to study acute rejection and immunosuppression in the cat. Twelve adult cats received a MLC incompatible flap. Six of the cats received cyclosporine oral solution and prednisolone (0.5 mg/kg/24 hr) for 100 days and six cats were not treated. Trough whole-blood levels of cyclosporine in the treatment group were maintained at approximately 750 ng/ml for 70 days, then 500 ng/ml for the remaining 30 days. Three flaps failed due to technical problems; 5 flaps were studied in the treatment group and 4 in the untreated group. All 5 flaps in the treatment group survived the 100 day treatment period and were rejected 30±26 days following cessation of treatment. Prior to discontinuation of treatment, with the exception of one cat, inflammatory changes associated with rejection were not observed in biopsy specimen. The flaps in the untreated group survived 13±1.5 days. Histopathologic examination of the flaps revealed little difference in the appearance of acute rejection and rejection after cessation of therapy. The most prominent lesion was a vasculitis with extensive perivascular lymphohistocytic inflammation. The lymphoid infiltrates consisted predominantly of T cells of both major classes (CD4 and CD8). Full-thickness epidermal necrosis and subsequent bacterial invasion followed vascular compromise.

AB - The gracilis musculocutaneous flap was developed as an allograft model to study acute rejection and immunosuppression in the cat. Twelve adult cats received a MLC incompatible flap. Six of the cats received cyclosporine oral solution and prednisolone (0.5 mg/kg/24 hr) for 100 days and six cats were not treated. Trough whole-blood levels of cyclosporine in the treatment group were maintained at approximately 750 ng/ml for 70 days, then 500 ng/ml for the remaining 30 days. Three flaps failed due to technical problems; 5 flaps were studied in the treatment group and 4 in the untreated group. All 5 flaps in the treatment group survived the 100 day treatment period and were rejected 30±26 days following cessation of treatment. Prior to discontinuation of treatment, with the exception of one cat, inflammatory changes associated with rejection were not observed in biopsy specimen. The flaps in the untreated group survived 13±1.5 days. Histopathologic examination of the flaps revealed little difference in the appearance of acute rejection and rejection after cessation of therapy. The most prominent lesion was a vasculitis with extensive perivascular lymphohistocytic inflammation. The lymphoid infiltrates consisted predominantly of T cells of both major classes (CD4 and CD8). Full-thickness epidermal necrosis and subsequent bacterial invasion followed vascular compromise.

UR - http://www.scopus.com/inward/record.url?scp=0025805418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025805418&partnerID=8YFLogxK

M3 - Article

C2 - 2048193

AN - SCOPUS:0025805418

VL - 51

SP - 1170

EP - 1175

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -